NCT05960240 - Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects. | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

August 30, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

April 30, 2026

Conditions

Chronic Hepatitis b

Interventions

DRUG

AB-101

AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.

DRUG

Placebo

A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.

DRUG

Nucleos(t)ide Analogue

Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B.

Trial Locations (10)

Unknown

Prince of Wales Hospital, Hong Kong

Queen Mary Hospital - PPDS, Hong Kong

ASST Papa Giovanni XXIII -Osepedale, Bergamo

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan

"Clinial Republican Hospital Timofei Mosneaga", Chisinau

New Zealand Clinical Research Auckland, Grafton

"Clinical Republican Hospital Timofei Mosneaga, ARENSIA E. M.", Bucharest

National University Hospital, Singapore

Singapore General Hospital, Singapore

Municipal Non-Profit Enterprise Kyiv City Clinical Hospital No12 Executive Body of Kyiv City Council, Kyiv